The Latest Cardiac and Vascular News
PARIS–(BUSINESS WIRE)–BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, presented two groundbreaking studies during the oral plenary and concurrent sessions on January 30th at the Society for Maternal-Fetal Medicine (SMFM) 2025 Pregnancy Meeting, held in Aurora, Colorado. As the first major unveiling of the […]
Robust evidence of the clinical benefit of WINREVAIR demonstrated in the STELLAR and ZENITH studies resulted in a loss of clinical equipoise in the HYPERION study January 30, 2025 06:45 AM Eastern Standard Time RAHWAY, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced […]
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the start of a Randomized Study of the Auryon Atherectomy System Used in Combination with […]
WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), today announced positive interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45, a long-acting, Fc-relaxin fusion protein. The interim data showed that a single intravenous dose of TX45 resulted in meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). In the trial, TX45 was well tolerated in patients with PH-HFpEF with no serious or severe adverse events.
PASADENA, Calif., Jan. 28, 2025 /PRNewswire/ — Huntington Medical Research Institutes (HMRI), a pioneer in scientific research with a track record of groundbreaking discoveries, provides crucial insights into predicting the long-term risk for cardiovascular damage from e-cigarettes…
LEIDEN, The Netherlands–(BUSINESS WIRE)–Ncardia, a leading human induced pluripotent stem cell (hiPSC) technology company, today announced the launch of Ncyte® Heart in a Box, a breakthrough 3D cardiac microtissue model designed to drive innovation in cardiovascular research and drug discovery. “With Ncyte® Heart in a Box, we are empowering researchers to […]
SUNNYVALE, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) — BioCardia, Inc. [NASDAQ: BCDA] today announced that the results of its double-blind randomized placebo-controlled CardiAMP HF Phase 3 study have been accepted for presentation in a late-breaking symposium at the American College of Cardiology 2025 Scientific Sessions, taking place in Chicago, March 29-31, 2025.
Revolutionizing care from minimally invasive surgery to comprehensive outpatient services RIYADH, Saudi Arabia, Jan. 27, 2025 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSHRC) has solidified its position as a regional leader in advanced cardiac care. Its Heart Centre combines cutting-edge technology with exceptional outcomes, making it the top choice for patients from Saudi Arabia…
Full IDE Data Set Demonstrates Sustained Benefit at One Year with Use of AMDS in Acute DeBakey Type I (ADTI) Dissections Complicated by Malperfusion ATLANTA, Jan. 27, 2025 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic…
Two patients at MedStar Union Memorial Hospital receive recently FDA-approved Evoque Tricuspid Valve Replacements for severe tricuspid regurgitation. BALTIMORE, Jan. 24, 2025 /PRNewswire/ — In two separate procedures, MedStar Health cardiac experts at MedStar Union Memorial Hospital…
